Please use this identifier to cite or link to this item:
Title: Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Authors: Lal, Himal
Cunningham, Anthony L.
Godeaux, Olivier
Chlibek, Roman
Diez-Domingo, Javier
Hwang, Shinn-Jang
Levin, Myron J.
McElhaney, Janet E.
Poder, Airi
Puig-Barbera, Joan
Vesikari, Timo
Watanabe, Daisuke
Weckx, Lily [UNIFESP]
Zahaf, Toufik
Heineman, Thomas C.
ZOE-50 Study Grp
GSK Vaccines
Westmead Millennium Inst Med Res
Univ Sydney
Univ Def
Fdn Fomento Invest Sanitaria & Biomed
Taipei Vet Gen Hosp
Natl Yang Ming Univ
Univ Colorado
Adv Med Res Inst Canada
Tartu Univ Hosp
Univ Tampere
Aichi Med Univ
Universidade Federal de São Paulo (UNIFESP)
Issue Date: 28-May-2015
Publisher: Massachusetts Medical Soc
Citation: New England Journal of Medicine. Waltham: Massachusetts Medical Soc, v. 372, n. 22, p. 2087-2096, 2015.
Abstract: BackgroundIn previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01(B) adjuvant system (called HZ/su) had a clinically acceptable safety profile and elicited a robust immune response.MethodsWe conducted a randomized, placebo-controlled, phase 3 study in 18 countries to evaluate the efficacy and safety of HZ/su in older adults (>= 50 years of age), stratified according to age group (50 to 59, 60 to 69, and >= 70 years). Participants received two intramuscular doses of the vaccine or placebo 2 months apart. the primary objective was to assess the efficacy of the vaccine, as compared with placebo, in reducing the risk of herpes zoster in older adults.ResultsA total of 15,411 participants who could be evaluated received either the vaccine (7698 participants) or placebo (7713 participants). During a mean follow-up of 3.2 years, herpes zoster was confirmed in 6 participants in the vaccine group and in 210 participants in the placebo group (incidence rate, 0.3 vs. 9.1 per 1000 person-years) in the modified vaccinated cohort. Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence interval [CI], 93.7 to 99.0; P<0.001). Vaccine efficacy was between 96.6% and 97.9% for all age groups. Solicited reports of injection-site and systemic reactions within 7 days after vaccination were more frequent in the vaccine group. There were solicited or unsolicited reports of grade 3 symptoms in 17.0% of vaccine recipients and 3.2% of placebo recipients. the proportions of participants who had serious adverse events or potential immune-mediated diseases or who died were similar in the two groups.ConclusionsThe HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or older was similar to that in the other two age groups. (Funded by GlaxoSmithKline Biologicals; ZOE-50 ClinicalTrials.govnumber, NCT01165177.)
ISSN: 0028-4793
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.